Trial Profile
A Phase 1, Open-Label, Single Center Study to Evaluate the Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast (CC-10004) in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Ankylosing spondylitis; Atopic dermatitis; Behcet's syndrome; Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Amgen; Celgene Corporation
- 28 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Sep 2014 New trial record